This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | C67 (C67.0 trigone of bladder, C67.1 dome of bladder, C67.2 anterior wall of bladder, C67.3 posterior wall, C67.4 lateral wall of bladder, C67.5 bladder neck, C67.6 ureteric orifice, C67.7 urachus, C67.8 overlapping sites, C67.9 bladder, unspecified) |
| B. Synonyms | Bladder cancer, urothelial bladder carcinoma, transitional cell carcinoma of the bladder (TCC), non-muscle-invasive bladder cancer (NMIBC), muscle-invasive bladder cancer (MIBC), squamous cell carcinoma of the bladder |
| C. Adult onset | Very high — occurs mainly at ages 65–75. Men are affected 3–4 times more often than women. Among the top 5 cancers in men in Korea. Smoking and occupational carcinogen exposure are the main risk factors. Long-term follow-up is needed due to a high recurrence rate. |
| Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5% | |
One of the most important milestones in the history of bladder cancer is the discovery of occupational carcinogens. With the growth of the German dye industry in the 19th century, clusters of bladder cancer were observed in certain occupational groups, and in 1895 the German physician Ludwig Rehn first documented a markedly high incidence of bladder cancer among workers in synthetic aniline dye factories. This observation was the starting point of research on industrial carcinogens, and aromatic amines such as β-naphthylamine (2-naphthylamine), benzidine, and 4-aminobiphenyl were subsequently identified as key chemicals in bladder carcinogenesis.
Intravesical BCG (Bacillus Calmette-Guérin) immunotherapy was first reported by Morales et al. in 1976 and was an innovative concept that remains the standard treatment for high-risk non-muscle-invasive bladder cancer (NMIBC) to this day. BCG is a form of immunotherapy that induces a local immune response within the bladder to eliminate tumor cells and is an early success story of tumor immunology. Since 2016, with the introduction of atezolizumab, pembrolizumab, and in 2023 enfortumab vedotin + pembrolizumab combination therapy, the landscape of systemic treatment for bladder cancer has changed rapidly.
In Korea, bladder cancer is the fifth most common cancer in men, and the number of new cases continues to increase due to smoking rates and population aging. The bladder cancer clinical practice guidelines of the Korean Urological Association provide the basis for standard care in Korea.
The most important risk factors for bladder cancer are smoking and occupational carcinogen exposure. Smoking increases bladder cancer risk 2–4 times compared with nonsmokers, and an estimated 50–65% of all bladder cancers are attributable to smoking. A dose-response relationship proportional to smoking amount (pack-years) and duration has been established. Bladder carcinogens from smoking, such as acrolein, 4-aminobiphenyl, and NNK (a nitrosamine), are metabolized in the liver and then come into direct contact with the bladder epithelium via the urine.
Occupational aromatic amine exposure: exposure to aromatic amines such as β-naphthylamine, benzidine, and o-toluidine among workers in the dye, rubber, leather, chemical, aluminum, textile, and printing industries greatly increases bladder cancer risk. Occupational exposure to these substances accounts for 25–30% of all bladder cancers. Schistosomiasis (Schistosoma haematobium) infection is a major risk factor for squamous cell carcinoma of the bladder and is common in the Middle East and Africa. Chronic urinary tract infection and urinary stones also increase bladder cancer risk through bladder irritation and inflammation. Radiation exposure (history of pelvic radiation therapy), environmental arsenic exposure, and use of the anticancer drug cyclophosphamide are associated with bladder cancer risk. The 3-fold higher incidence in men is explained by differences in smoking history, occupational exposure, sex hormones, and so on.
Urothelial carcinoma of the bladder is divided into subtypes according to two representative molecular pathways. In low-grade papillary tumors (the majority of NMIBC), FGFR3 activating mutations (exon 7, 10, 15 mutations; in 50–60%) and PIK3CA mutations (25%) are key molecular events. TERT promoter mutations (C228T, C250T) are the most common somatic mutations, found in 60–80% of all bladder cancers, and are used as biomarkers for early development and recurrence surveillance.
In high-grade invasive tumors (MIBC), TP53 mutations (~50%), RB1 loss (~25%), CDKN2A (p16) loss (~50%), and ERCC2 mutations (a DNA repair gene, ~10%) are the main molecular abnormalities. ERCC2 mutations are associated with cisplatin sensitivity and are used to predict response to neoadjuvant chemotherapy. TCGA (The Cancer Genome Atlas) classified MIBC into molecular subtypes (luminal papillary, luminal unstable, luminal non-specified, stroma-rich, basal squamous), and treatment response and prognosis differ by subtype. HER2 (ERBB2) amplification (10%) is the target of clinical studies of HER2-targeted agents. From a pharmacogenomic perspective, FGFR3 mutations predict response to erdafitinib, and PD-L1 expression/TMB/MSI are biomarkers predicting response to immune checkpoint inhibitors.
Bladder cancer is the 10th most common cancer worldwide; in 2020, about 573,000 new cases were diagnosed and 213,000 people died. The incidence is 3–4 times higher in men than in women. Incidence is highest in Southern Europe and North America and relatively low in East Asia. Incidence is higher in high-income countries than in low-income countries, which is related to differences in smoking patterns, occupational exposure, and access to diagnosis.
In Korea, bladder cancer is among the top 5 cancers in men, and despite declining smoking rates, the absolute number of patients is increasing due to population aging. The male-to-female ratio is about 3:1. 75–85% of all bladder cancers are diagnosed as non-muscle-invasive bladder cancer (NMIBC), in which the recurrence rate reaches 50–80%, making long-term follow-up essential. The occupational distribution of bladder cancer depends on the level of industrialization and occupational composition, and high incidence is observed in regions with developed chemical and textile industries. Worldwide, bladder cancer mortality is declining in developed countries, but mortality is high in developing countries due to limited access.
The pathogenesis of urothelial carcinoma of the bladder is explained by the multistep carcinogenesis model. Chemical carcinogens (smoking metabolites, aromatic amines, acrolein, etc.) dissolved in urine repeatedly contact the bladder epithelium, forming DNA adducts and accumulating mutations. This process progresses over decades, transitioning from bladder epithelial atypia → carcinoma in situ (CIS) → invasive carcinoma.
In the low-grade papillary pathway, FGFR3 mutations constitutively activate the FGF signaling pathway, promoting cell proliferation. This pathway progresses relatively slowly, with a low risk of conversion to muscle invasion. In the high-grade invasive pathway, TP53 mutations, RB1 loss, and CDKN2A loss disrupt the G1/S checkpoint, enabling unlimited proliferation of abnormal cells, and together with activation of the basal program, epithelial-mesenchymal transition (EMT) occurs and invasive and metastatic capacity is acquired. The key mechanism of BCG treatment is the induction of a local Th1 immune response in the bladder epithelium, so that CD8+ cytotoxic T lymphocytes eliminate tumor cells. Immune checkpoint inhibitors (PD-1/PD-L1 blockade) act by restoring T-cell recognition and destruction of tumor cells.
The most common and important symptom of bladder cancer is painless intermittent gross hematuria. Hematuria occurs in 80–90% of all patients with bladder cancer and ranges from pink to dark brown. Even if the hematuria resolves spontaneously, its cause must be determined. Painless hematuria, especially in elderly smokers, is a warning symptom strongly suggestive of bladder cancer.
Bladder irritation symptoms such as urinary frequency, urgency, and burning on urination (dysuria) may occur and are related to local irritation by the intravesical tumor or to carcinoma in situ (CIS) lesions. If there is bladder outlet obstruction, a weak urinary stream, delayed voiding, and a sensation of residual urine may accompany it. In advanced bladder cancer, flank pain due to hydronephrosis, pelvic and lower back pain, lower limb edema (lymph node metastasis), and systemic symptoms such as weight loss and fatigue may occur. Microscopic hematuria should also not be ignored; in high-risk patients (smokers, aged 50 or older), microscopic hematuria requires an active search for the cause.
On physical examination, early bladder cancer has no specific signs in most cases. Positive hematuria on urinalysis or urine dipstick is the key finding. Urine cytology has high specificity for detecting high-grade urothelial carcinoma (specificity >90%) but low sensitivity for low-grade tumors (30–40%). Urinary tumor markers such as NMP22 (nuclear matrix protein 22) and BTA stat (bladder tumor antigen) are used as adjuncts but have a high false-positive rate.
Cystoscopy is the standard procedure for diagnosing bladder cancer and directly visualizes the number, location, size, and morphology (papillary/flat/sessile) of tumors. On bimanual examination under anesthesia (EUA, Examination Under Anesthesia), a fixed bladder or palpable mass suggests an advanced lesion. Abdominal and pelvic CT or MRI evaluates bladder wall thickening, tumor protrusion, lymph node enlargement, distant metastasis, and so on. Enhanced cystoscopy (blue-light/fluorescence cystoscopy, using 5-ALA or HAL) is useful for detecting flat lesions (CIS) and satellite lesions that are easily missed on conventional white-light cystoscopy.
The effectiveness of mass screening for bladder cancer in the general population has not yet been established. Screening using hematuria testing (urine dipstick) has been examined in some studies, but the high false-positive rate leads to excessive referrals for diagnostic cystoscopy. However, active screening is recommended in high-risk groups.
Screening criteria for high-risk groups: ① men aged 50 or older with a smoking history of 30 pack-years or more, ② workers with occupational aromatic amine exposure, ③ patients under follow-up after previous treatment for bladder cancer. In these groups, urinalysis (including hematuria) and urine cytology are performed periodically. Follow-up of patients with a history of bladder cancer: because the recurrence rate after NMIBC treatment reaches 50–80%, cystoscopic follow-up is needed for at least 5 years, and lifelong in high-risk patients. Bladder cancer is not included in the Korean National Cancer Screening Program, but early visits to medical institutions for asymptomatic hematuria and appropriate testing are effectively the main route to early detection.
The standard procedures for diagnosing bladder cancer are cystoscopy and transurethral resection of bladder tumor (TURBT). After visualizing the tumor with cystoscopy, TURBT is performed, achieving diagnosis and treatment at the same time. The TURBT specimen is used to confirm the histologic type, grade, and depth of invasion (Ta, T1, T2 or higher) to decide the treatment plan. For high-grade or T1 or higher lesions, repeat TURBT (re-TURBT) is performed after 4–6 weeks to check for residual tumor and improve staging accuracy.
For staging, abdominal and pelvic CT (CT urography) is performed to evaluate the extent of local invasion, lymph node metastasis, and distant metastasis of bladder cancer. MRI (mpMRI of the bladder) provides better soft-tissue resolution than CT for evaluating the depth of muscle invasion. Urine cytology (voided urine cytology, washing cytology) and FISH (UroVysion) are used as adjunctive diagnostics. After obtaining tissue, FGFR3 mutation analysis, PD-L1 expression, TMB, and MSI testing are performed to assess eligibility for targeted agents and immune checkpoint inhibitors. NMIBC risk classification (EAU low-, intermediate-, and high-risk criteria) is the key tool for determining treatment intensity.
Treatment is broadly divided into non-muscle-invasive (NMIBC) and muscle-invasive (MIBC) disease. In NMIBC, intravesical therapy according to risk is given after TURBT. In low-risk disease, a single intravesical instillation of mitomycin C (MMC) immediately after TURBT is recommended. In high-risk disease (T1G3, CIS, multiple/recurrent high-grade), intravesical BCG immunotherapy (6-week induction + maintenance for at least 1 year) is standard. In BCG-unresponsive high-risk NMIBC, radical cystectomy or pembrolizumab (FDA-approved), nadofaragene firadenovec, or intravesical docetaxel+gemcitabine combination therapy are alternatives.
In MIBC (T2 or higher), the standard treatment is preoperative neoadjuvant cisplatin-based chemotherapy (DDMVAC or GC) + radical cystectomy (RC). Urinary diversion (ileal conduit, neobladder, etc.) is performed at the same time as cystectomy. Radiation-based bladder-preserving therapy (trimodality therapy: TURBT + concurrent chemotherapy + radiation therapy) is selectively possible in patients who do not want surgery. In metastatic bladder cancer (first-line), GC (gemcitabine + cisplatin) is standard in cisplatin-eligible patients, and recently enfortumab vedotin + pembrolizumab (EV+P) combination therapy has shown superior efficacy in both cisplatin-eligible and -ineligible patients and is emerging as the new first-line standard (EV-302/KEYNOTE-869 trial). In the second line and beyond, enfortumab vedotin monotherapy, sacituzumab govitecan, erdafitinib (FGFR mutation-positive), pembrolizumab, and others are used.
The prognosis of bladder cancer varies greatly according to the depth of invasion (stage).
| Stage/classification | 5-year survival rate (approximate) |
|---|---|
| Ta (papillary, noninvasive) | 90–95% |
| T1 (lamina propria invasion) | 70–85% |
| T2 (muscle layer invasion, MIBC) | 55–70% |
| T3 (perivesical fat) | 30–50% |
| T4 / lymph node metastasis | 20–30% |
| Distant metastasis (M1) | 5–15% (improving in the EV+P era) |
NMIBC has a high recurrence rate (50–80%) and a heavy treatment burden, but bladder cancer-specific mortality is low. In MIBC, optimal neoadjuvant chemotherapy and RC are key to improving long-term survival. In metastatic bladder cancer, the introduction of EV+P combination therapy has greatly improved overall survival (median overall survival 31.5 months, EV-302 trial). In FGFR3 mutation-positive patients, the response rate to erdafitinib is 40% or higher, and MSI-H/TMB-H patients respond well to immune checkpoint inhibitors.
The most powerful and well-evidenced method of preventing bladder cancer is smoking cessation. Because smoking contributes to 50–65% of all bladder cancers, smoking cessation alone can reduce the bladder cancer burden by more than half. After quitting smoking, bladder cancer risk gradually declines, approaching the level of nonsmokers after 10–15 years. Public health policies such as smoking prevention education, improved access to smoking cessation clinics, and tobacco tax increases are directly linked to bladder cancer prevention.
Reducing occupational exposure: occupational bladder cancer is prevented by tightening exposure standards for aromatic amines (β-naphthylamine, benzidine, etc.), using substitute substances, wearing personal protective equipment, and regular occupational health examinations. Under Korea's Occupational Safety and Health Act, special health examinations are mandatory for workers exposed to bladder carcinogens. There are epidemiological studies suggesting that increased fluid intake (1.5 L or more per day) can lower bladder cancer risk by shortening the residence time of carcinogens in urine. Fruit and vegetable (antioxidant) intake, correction of excess weight, and adequate physical activity are also suggested as protective factors. Avoiding herbal medicines containing aristolochic acid and practicing prevention of sexually transmitted diseases (using safe drinking water to prevent urinary schistosomiasis) are also effective prevention strategies in certain regions.